Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy

Journal of Neuroimmunology

Volumn 214, Issue 1-2, 2009, Pages 93-100

  Kim, Hye Jung ^a   Jung, Cha Gyun ^a   Dukala, Danuta ^a   Bae, Hyun ^a   Kakazu, Rafael ^a   Wollmann, Robert ^a   Soliven, Betty ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CIDP; FTY720; Guillain Barr syndrome; NOD mice; S1P receptors; SEW2871

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; CYTOKINE; FINGOLIMOD; MYELIN PROTEIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; MOUSE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; POLYNEUROPATHY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SPONTANEOUS AUTOIMMUNE POLYNEUROPATHY;

ANIMALS; AUTOIMMUNITY; BLOOD-NERVE BARRIER; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; ELECTROPHYSIOLOGY; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; OXADIAZOLES; POLYMERASE CHAIN REACTION; POLYNEUROPATHIES; PROPYLENE GLYCOLS; SCHWANN CELLS; SEVERITY OF ILLNESS INDEX; SPHINGOSINE; SPLEEN; THIOPHENES;

EID: 69949124388     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.07.006     Document Type: Article

References (43)

1. Allende M.L., Sasaki T., Kawai H., Olivera A., Mi Y., van Echten-Deckert G., Hajdu R., Rosenbach M., Keohane C.A., Mandala S., Spiegel S., and Proia R.L. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279 (2004) 52487-52492
2. Balatoni B., Storch M.K., Swoboda E.M., Schonborn V., Koziel A., Lambrou G.N., Hiestand P.C., Weissert R., and Foster C.A. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 74 (2007) 307-316
3. Barber S.C., Mellor H., Gampel A., and Scolding N.J. S1P and LPA trigger Schwann cell actin changes and migration. Eur. J. Neurosci. 19 (2004) 3142-3150
4. Bour-Jordan H., Thompson H.L., and Bluestone J.A. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J. Immunol. 175 (2005) 5649-5655
5. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115 (2007) 84-105
6. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., and Lynch K.R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277 (2002) 21453-21457
7. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., and Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160 (1998) 5037-5044
8. Cinamon G., Zachariah M.A., Lam O.M., Foss Jr. F.W., and Cyster J.G. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat. Immunol. 9 (2008) 54-62
9. Coelho R.P., Payne S.G., Bittman R., Spiegel S., and Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 323 (2007) 626-635
10. Foster C.A., Mechtcheriakova D., Storch M.K., Balatoni B., Howard L.M., Bornancin F., Wlachos A., Sobanov J., Kinnunen A., and Baumruker T. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 29 (2009) 254-266
11. Fujino M., Funeshima N., Kitazawa Y., Kimura H., Amemiya H., Suzuki S., and Li X.K. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305 (2003) 70-77
12. Gonzalez-Cabrera P.J., Hla T., and Rosen H. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J. Biol. Chem. 282 (2007) 7254-7264
13. Graler M.H., and Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. Faseb J. 18 (2004) 551-553
14. Hadden R.D., Sharrack B., Bensa S., Soudain S.E., and Hughes R.A. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53 (1999) 57-61
15. Hahn A.F. Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Rev. Neurol. (Paris) 152 (1996) 328-332
16. Hila S., Soane L., and Koski C.L. Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD. Glia 36 (2001) 58-67
17. Hofmann M., Brinkmann V., and Zerwes H.G. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int. Immunopharmacol. 6 (2006) 1902-1910
18. Hughes J.E., Srinivasan S., Lynch K.R., Proia R.L., Ferdek P., and Hedrick C.C. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ. Res. 102 (2008) 950-958
19. Iwase T., Jung C.G., Bae H., Zhang M., and Soliven B. Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells. J. Neurochem. 94 (2005) 1488-1499
20. Jaillard C., Harrison S., Stankoff B., Aigrot M.S., Calver A.R., Duddy G., Walsh F.S., Pangalos M.N., Arimura N., Kaibuchi K., Zalc B., and Lubetzki C. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25 (2005) 1459-1469
21. Jung C.G., Kim H.J., Miron V.E., Cook S., Kennedy T.E., Foster C.A., Antel J.P., and Soliven B. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55 (2007) 1656-1667
22. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., and Radue E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (2006) 1124-1140
23. Kim H.J., Jung C.G., Jensen M.A., Dukala D., and Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J. Immunol. 181 (2008) 8753-8760
24. Kobashi H., Yaoi T., Oda R., Okajima S., Fujiwara H., Kubo T., and Fushiki S. Lysophospholipid receptors are differentially expressed in rat terminal Schwann cells, as revealed by a single cell rt-PCR and in situ hybridization. Acta Histochem. Cytochem. 39 (2006) 55-60
25. Lan Y.Y., De Creus A., Colvin B.L., Abe M., Brinkmann V., Coates P.T., and Thomson A.W. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am. J. Transplant 5 (2005) 2649-2659
26. Louvet C., Kabre B.G., Davini D.W., Martinier N., Su M.A., DeVoss J.J., Rosenthal W.L., Anderson M.S., Bour-Jordan H., and Bluestone J.A. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J. Exp. Med. 206 (2009) 507-514
27. Maeda Y., Matsuyuki H., Shimano K., Kataoka H., Sugahara K., and Chiba K. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J. Immunol. 178 (2007) 3437-3446
28. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
29. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., and Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
30. Mehling M., Brinkmann V., Antel J., Bar-Or A., Goebels N., Vedrine C., Kristofic C., Kuhle J., Lindberg R.L., and Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71 (2008) 1261-1267
31. Miron V.E., Hall J.A., Kennedy T.E., Soliven B., and Antel J.P. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 173 (2008) 1143-1152
32. Nagano S., Takeda M., Ma L., and Soliven B. Cytokine-induced cell death in immortalized Schwann cells: roles of nitric oxide and cyclic AMP. J. Neurochem. 77 (2001) 1486-1495
33. Ogata T., Iijima S., Hoshikawa S., Miura T., Yamamoto S., Oda H., Nakamura K., and Tanaka S. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J. Neurosci. 24 (2004) 6724-6732
34. Oo M.L., Thangada S., Wu M.T., Liu C.H., Macdonald T.L., Lynch K.R., Lin C.Y., and Hla T. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282 (2007) 9082-9089
35. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., and Zinkernagel R.M. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164 (2000) 5761-5770
36. Salomon B., Rhee L., Bour-Jordan H., Hsin H., Montag A., Soliven B., Arcella J., Girvin A.M., Padilla J., Miller S.D., and Bluestone J.A. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J. Exp. Med. 194 (2001) 677-684
37. Sawicka E., Dubois G., Jarai G., Edwards M., Thomas M., Nicholls A., Albert R., Newson C., Brinkmann V., and Walker C. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J. Immunol. 175 (2005) 7973-7980
38. Setoguchi R., Hori S., Takahashi T., and Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201 (2005) 723-735
39. Vallat J.M., Hahn A.F., Leger J.M., Cros D.P., Magy L., Tabaraud F., Bouche P., and Preux P.M. Interferon beta-1a as an investigational treatment for CIDP. Neurology 60 (2003) S23-28
40. Webb M., Tham C.S., Lin F.F., Lariosa-Willingham K., Yu N., Hale J., Mandala S., Chun J., and Rao T.S. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153 (2004) 108-121
41. Wei S.H., Rosen H., Matheu M.P., Sanna M.G., Wang S.K., Jo E., Wong C.H., Parker I., and Cahalan M.D. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat. Immunol. 6 (2005) 1228-1235
42. Whetzel A.M., Bolick D.T., Srinivasan S., Macdonald T.L., Morris M.A., Ley K., and Hedrick C.C. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ. Res. 99 (2006) 731-739
43. Zhang Z., Zhang Z.Y., Fauser U., and Schluesener H.J. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp. Neurol. 210 (2008) 681-690